Researchers unveiled a high-resolution analytical method for quantifying DNA content within AAV capsids, targeting a persistent viral-vector characterization bottleneck. The approach uses electrical mobility measurements correlated to mass to quantify capsid-associated DNA more precisely. AAV vector development and clinical translation often require tight control over DNA packaging and impurities, because variability can complicate comparability, potency, and safety assessments. The new technique is framed as a way to improve resolution in DNA content characterization without relying solely on more indirect assays. The development is likely to interest teams working on comparability strategies across manufacturing scale-up and tech transfer. If adopted, a more precise and scalable AAV analytics workflow could reduce uncertainty in release testing and help accelerate iterative process development for gene therapy programs.